Evidence map›Paper›PMID 35333696›Full record

ArticleBioengineered2022

Necdin, one of the important pathway proteins in the regulation of osteosarcoma progression by microRNA-200c.

Jian Li, Zhuangzhuang Wu, Jiani Wang, Taiyong Wu, Zhen Shen, Long Zhang, Jia Lv, Junjun Bai, Yi Feng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jian LiSecond Clinical Medical College, Shanxi Medical University, Taiyuan, ShanXi, China.
Zhuangzhuang WuDepartment of Orthopaedics, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Jiani WangSecond Clinical Medical College, Shanxi Medical University, Taiyuan, ShanXi, China.
Taiyong WuSecond Clinical Medical College, Shanxi Medical University, Taiyuan, ShanXi, China.
Zhen ShenSecond Clinical Medical College, Shanxi Medical University, Taiyuan, ShanXi, China.
Long ZhangSecond Clinical Medical College, Xiamen University, Xiamen, Fujian, China.
Jia LvDepartment of Orthopaedics, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Junjun BaiDepartment of Orthopaedics, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Yi FengDepartment of Orthopaedics, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID 0000-0002-6770-7399
Shanxi Medical University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-200c (miR-200c) generally acts as a tumor suppressor in multiple cancer types and a promising therapeutic target in tumorigenesis. However, only a few studies have explained the role of miR-200c in the development of osteosarcoma (OS). In this study, we investigated the role of miR-200c in OS progression and identified the regulatory pathway protein NDN involved in inhibiting the occurrence and development of OS. Firstly, we found that miR-200c is downregulated in OS cells and tissues. As well,

Indexed as

Bone NeoplasmsMicroRNAsNerve Tissue ProteinsNuclear ProteinsOsteosarcoma3' Untranslated RegionsAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticMice3' Untranslated RegionsMicroRNAsMirn200 microRNA, mousenecdinNerve Tissue ProteinsNuclear ProteinsinvasionmicroRNA-200cmigrationnecdinOsteosarcomaproliferation

Identifiers

PMID35333696
PMCPMC9161937
OpenAlexW4220688041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.